Moderna Therapeutics
Main (gene editing) focus: Next-generation in vivo gene-editing therapeutics
Company stage: Commercial
Diseases: Undisclosed
Genome editing tool: Undisclosed
Funding stage: Public (NASDAQ:MRNA)
Location: Cambridge, MA, USA
Website: https://www.modernatx.com/
Pipeline: https://www.modernatx.com/pipeline
Partners: Metagenomi
Moderna Therapeutics is a vaccine developer, mostly known for its involvement and efforts in the development and commercialisation of its mRNA-based COVID-19 vaccine. In relation to genome editing, the company has disclosed a collaboration with Metagenomi to develop next-generation in vivo gene-editing therapeutics. The collaboration will see the use of Metagenomi's gene-editing platform in combination with Moderna's mRNA lipid nanoparticle (LNP) technologies to edit multiple udisclosed targets.